Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,354.03 +62.69 (+1.18%) Dow
38,807.33 +96.04 (+0.25%) Nasdaq
17,187.90 +330.86 (+1.96%) Bitcoin USD
71,286.16 +955.01 (+1.36%) CMC Crypto 200
1,520.50 +46.76 (+3.17%)
ALLO Aug 2024 2.500 call
| Previous close | 0.5000 |
| Open | 0.4000 |
| Bid | 0.3000 |
| Ask | 0.9000 |
| Strike | 2.50 |
| Expiry date | 2024-08-16 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 304 |
GlobeNewswireAllogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in the TD Cowen 5th Annual Oncology Innovation Summit. TD Cowen 5th Annual Oncology Innovation SummitTuesday, May 28, 20249:30am PT/12:30pm ET The webcast will be posted to the Company's website at www.allogene.com
ZacksAllogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
- GuruFocus.com
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Exploring Allogene's Q1 performance, strategic initiatives in oncology, and financial maneuvers amidst a challenging landscape.
